By Pat Broderick
Daily Journal Staff Writer
The sour economy, coupled with recent mega-mergers of big pharmaceutical companies, could spell opportunity for baby biotechs.
With the mergers of Merck and Schering-Plough, Pfizer and Wyeth, and Roche Genentech Inc., "people worried that there would be few deals to be had," said John E. Wehrli. "But the new and larger players are hungrier and they need new opportunitie...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In